KR102008774B1 - Composition for improvement of memory and cognition ability, prevention, delay, treatment or improvement of Alzheimer's disease, comprising extracts of Ecklonia stolonifera, Curcuma longa Rhizoma, Zingiber officinale Roscoe and red ginseng - Google Patents

Abstract

The present invention relates to a composition for improving memory, improving cognition, preventing dementia, delaying, treating or improving gompi, turmeric, health and red ginseng extract as an active ingredient, and specifically, the extract of gompi, turmeric, health and red ginseng is effective. The present invention relates to pharmaceutical compositions and functional food compositions, which are contained as ingredients and exhibit an improvement in memory, cognition, dementia prevention, delay, treatment or improvement.
The composition of the present invention can improve memory and cognitive ability, such as short-term memory, spatial memory, spatial cognition, dementia without side effects through inhibition of beta-amyloid accumulation and beta-amyloid aggregation in the cerebral cortex and hippocampus Can be effectively prevented, delayed, ameliorated or treated.

Description

Composition for improvement of memory and cognition ability, prevention, delay, treatment or improvement of Alzheimer's containing gompi, turmeric, health and red ginseng extract as active ingredients disease, comprising extracts of Ecklonia stolonifera, Curcuma longa Rhizoma, Zingiber officinale Roscoe and red ginseng}

The present invention relates to a composition for improving memory, improving cognition, preventing dementia, delaying, treating or improving gompi, turmeric, health and red ginseng extract as an active ingredient, and specifically, the extract of gompi, turmeric, health and red ginseng is effective. The present invention relates to pharmaceutical compositions and functional food compositions, which are contained as ingredients and exhibit an improvement in memory, cognition, dementia prevention, delay, treatment or improvement.

As of 2014, Korea has already entered the aging society, and as of 2014, the elderly population accounted for 12.7%, and the number of dementia patients is increasing rapidly. This reality not only degrades the quality of life of individuals, but also becomes a big social and national problem as the national competitiveness decreases due to excessive medical expenses.

Currently, acetylcholine esterase inhibitors, donepezil, galantamine and rivastigmine, are used in clinical trials to improve dementia, but there are no effective treatments because of low treatment efficiency and severe side effects.

Dementia is caused by irreversible destruction of the brain's nerves due to brain atrophy, reduction of nerve cells, and the appearance of senile plaques, which accompany various acquired cognitive impairment symptoms such as memory, speech and behavioral disorders. Refers to the syndrome. Dementia is classified as Alzheimer's disease, degenerative diseases caused by vascular dementia and Parkinson's disease, metabolic diseases caused by hypothyroidism, brain tumors or infectious diseases, and the like.

In the brain tissues of Alzheimer's disease, pathological features such as the senile plaques generated around neurons and the neurofibrillary tangles produced intracellularly can be observed. Neurofibrillary tangles are formed by hyperphosphorylation of tau proteins, and in the elderly half, β-amyloid (Aβ) secreted out of cells is formed by aggregation around neurons.

Alzheimer's disease is classified into familial type and sporadic type, and more than 90% of all diseases are sporadic type mainly in elderly people over 65 years. In the familial type, mutations are known in genes such as amyloid precursor protein (APP), presenilin 1, and presenilin 2, and the sporadic type has been reported to be due to aging and ApoE4 alleles. The senile plaque caused by Aβ accumulation is a common pathology in both familial and sporadic types. Aβ is produced by the degradation of beta amyloid precursor protein APP (Amyloid precursor protein) by two types of proteases. The cleavage of amino terminus is β-secretase and the cleavage of carboxy terminus is γ-secretase. Γ-secretase, one of the targets for the development of Alzheimer's disease therapeutics, is present in a complex structure consisting of presenilin (PS), nicastrin, APH-1, a protein product of anteria pharynx defective gene, and PEN-2, a protein product of presenilin enhancer gene. do. However, this enzyme reacts with a number of substances such as Notch1, APLP1, ErbB4, Jagged, and CD44 as a substrate, and has a problem of developing an APP-specific inhibitor.

On the other hand, plants existing in nature are very diverse and often contain useful bioactive components, and these plant-derived components are generally superior in stability to compounds produced through artificial synthesis or modification. In addition, since it is a substance present in nature, it is naturally decomposed, so it is not decomposed or discharged, so there is little problem of accumulation in the body. Therefore, the present inventors have searched for substances effective for dementia from plants in order to develop drugs that can effectively prevent, delay, treat or improve dementia without side effects, and through these results, Korean Patent Nos. 10-1194091, 10- He developed the same technology as 1480899.

The present inventors have attempted screening for various plants in order to develop new and more effective substances for dementia, and found that there are possibilities of gompi, turmeric, health and red ginseng. Based on this, more detailed and full-scale studies can improve the memory and cognitive ability of extracts of these combinations such as short-term memory, spatial memory, and spatial cognitive ability, and inhibit beta-amyloid accumulation in the cerebral cortex and hippocampus. The present invention has been completed by confirming that the suppression of aggregation of amyloid can effectively prevent, delay, improve or treat dementia without side effects.

Republic of Korea Patent No. 10-1194091 Republic of Korea Patent No. 10-1480899

Accordingly, a main object of the present invention is to provide a pharmaceutical composition and a functional food composition containing plant-derived substances which can effectively prevent, delay, ameliorate or treat dementia without side effects.

According to one aspect of the present invention, the present invention provides a pharmaceutical composition for improving memory, improving cognitive ability, preventing dementia, or treating Gompi, turmeric, health and red ginseng extract as an active ingredient.

In the pharmaceutical composition of the present invention, the extract is preferably extracted using 10 to 90% (v / v) of ethanol as a solvent.

In the pharmaceutical composition of the present invention, the extract is preferably extracted from a mixture of 1 to 2 parts by weight of turmeric, 0.5 to 1.5 parts by weight and 0.5 to 1.5 parts by weight of red ginseng based on 1.5 parts by weight of gompi.

According to another aspect of the present invention, the present invention provides a functional food composition for improving memory, improving cognitive ability, preventing dementia, or improving gompi, turmeric, health and red ginseng extract as an active ingredient.

In the functional food composition of the present invention, the extract is preferably extracted using 10 to 90% (v / v) of ethanol as a solvent.

In the functional food composition of the present invention, the extract is preferably extracted from a mixture of 1 to 2 parts by weight of turmeric, 0.5 to 1.5 parts by weight and 0.5 to 1.5 parts by weight of red ginseng based on 1.5 parts by weight of gompi.

The composition of the present invention can improve memory and cognitive ability, such as short-term memory, spatial memory, spatial cognition, dementia without side effects through inhibition of beta-amyloid accumulation and beta-amyloid aggregation in the cerebral cortex and hippocampus Can be effectively prevented, delayed, ameliorated or treated.

1 is a block diagram showing a manufacturing process of an extract according to an embodiment of the present invention.
Figure 2 is a graph showing the results of the short-term memory improvement effect analysis experiment of the present invention composition.
Figure 3 is a graph showing the results of the spatial memory improvement effect analysis experiment of the present invention composition.
Figure 4 is a graph showing the results of the spatial cognitive improvement effect analysis experiment of the present invention composition.
Figure 5 shows the immunohistochemical staining results of the hippocampus of the beta-amyloid accumulation inhibitory effect analysis results of the composition of the present invention.
Figure 6 shows the immunohistochemical staining results of the cerebral cortical region of the beta-amyloid accumulation inhibitory effect analysis results of the composition of the present invention.
Figure 7 is a graph showing the immunohistochemical staining results of the hippocampus of the beta-amyloid accumulation inhibitory effect analysis results of the composition of the present invention.
Figure 8 is a graph showing the immunohistochemical staining of the cerebral cortical region of the beta-amyloid accumulation inhibitory effect analysis results of the composition of the present invention.
9 is a micrograph at 50,000 magnification (X50,000) of the beta-amyloid aggregation inhibitory effect assay result of the present invention composition.
10 is a photomicrograph of 100,000 magnification (X100,000) of the beta-amyloid aggregation inhibitory effect assay results of the composition of the present invention.
11 is a graph showing the results of the beta-amyloid aggregation inhibitory effect experiment of the present invention.

The present invention provides a pharmaceutical composition and functional food composition for improving memory, improving cognition, preventing dementia, delaying or treating gompi, turmeric, health and red ginseng extract as an active ingredient.

In dementia, the brain tissue of Alzheimer's disease can observe pathological features such as the elderly half of neurons and neurofibrillary tangles produced intracellularly. The neurofibrillary tangles are formed by hyperphosphorylation of tau protein. Geriatric half is formed by aggregation of beta-amyloid (Aβ) secreted out of cells around neurons. Thus, Αβ inhibitors may be important targets for the development of therapeutic agents for dementia. The present invention has completed the present invention by finding that the combination of gompi, turmeric, health and red ginseng is very effective in inhibiting the activity of Aβ.

Extract in the present invention means that the active ingredient is extracted using a solvent from the raw material.

Gompi ( Ecklonia stolonifera ) is a perennial seaweed with brown seaweed kelp seaweed seaweed in the present invention is preferably used as a raw material of the extract after the drying and grinding process.

Turmeric ( Curcuma longa Rhizoma) is a perennial herb of the monocotyledonous plant, Ginger-necked Gingiaceae, and in the present invention, it is preferable to use the root portion as a raw material of the extract after drying and crushing.

Health is a dried root stem of ginger ( Zingiber officinale Roscoe) in the present invention is preferably sliced and used as a raw material of the extract.

Red ginseng is steamed red ginseng dried by steaming ginseng, and in the present invention, it is preferable to use it as a raw material of the extract through a crushing process.

In the present invention, it is preferable to use 10 to 90% (v / v) of ethanol as a solvent for the preparation of the extract. More preferably, 30 to 70% (v / v) ethanol, and more preferably 40 to 60% (v / v) ethanol are preferably used. In addition, the amount of the solvent as described above is preferably 1 to 20 times by weight of the raw material, more preferably 5 to 15 times. The extraction temperature is preferably 70 to 100 ° C, more preferably 80 to 90 ° C. The extraction time is preferably 1 to 12 hours, more preferably 2 to 5 hours. According to such extraction conditions, it is possible to efficiently extract the components exhibiting the effects desired in the present invention from the raw materials. After extraction, it is preferably concentrated under reduced pressure at a temperature of 60 ° C. or lower and completely dried.

Extract of the present invention is preferably prepared by extracting from a mixture of 1 to 2 parts by weight of turmeric, 0.5 to 1.5 parts by weight and 0.5 to 1.5 parts by weight of red ginseng based on 1.5 parts by weight of gompi.

The compositions of the present invention can be administered orally or parenterally during clinical administration and can be used in the form of general pharmaceutical formulations. The pharmaceutical composition of the present invention may contain 0.1 to 50% by weight of the extract as an active ingredient based on the total weight of the composition.

The pharmaceutical composition of the present invention may be formulated into a conventional pharmaceutical formulation by selecting one or two or more pharmaceutically acceptable conventional carriers and one or two or more additives into the extract, which is the main ingredient. Dosage forms of the pharmaceutical compositions of the invention may be used in the form of their pharmaceutically acceptable salts, or may be used alone or in combination with other pharmaceutically active compounds, as well as in combination with suitable materials. The salt is not particularly limited as long as it is pharmaceutically acceptable, and for example, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid, hydrobromic acid, formic acid acetic acid, tartaric acid, lactic acid, citric acid, fumaric acid, maleic acid, succinic acid, methanesulfonic acid , Benzene sulfonic acid, toluene sulfonic acid, naphthalene sulfonic acid and the like can be used.

The pharmaceutical compositions of the present invention may be in various oral or parenteral formulations. When formulated, it may be prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc. which are commonly used. Solid form preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which form at least one excipient such as starch, calcium carbonate, sucrose or lactose (at least one compound). lactose), gelatin and the like can be mixed. In addition to simple excipients, lubricants such as magnesium stearate, talc and the like can also be used. Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, and syrups, and various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin, may be included. have. Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

The pharmaceutical composition of the present invention may include mineral-containing compounds such as vitamins B, C, E or beta carotene, Ca, Mg, and Zn, phospholipids such as lecithin, or compounds such as maltol and amino acids, as auxiliary ingredients, in addition to the main components. Of these, vitamin C, E or beta-carotene, maltol, and the like used in combination of two or three components is more preferable because it can increase or enhance the biological activity effect.

In addition to the above ingredients, in order to enhance the taste as a known additive, natural flavors such as plum, lemon, pineapple or herb, or natural fruit juice, natural pigments such as chlorophyllin, flavonoid, and fructose, sweet sugar, Honey, sugar alcohols, sugars, and other acidifying agents such as citric acid and sodium citrate can be used.

The subject to which the pharmaceutical composition of the present invention can be applied is a vertebrate, preferably a mammal, more preferably an experimental animal such as a rat, mouse, rabbit, guinea pig, hamster, dog, cat, and most preferably Are protozoan animals such as chimpanzees and gorillas.

The pharmaceutical composition of the present invention may be administered orally or parenterally, and when parenteral administration, it is preferable to select an external skin or intraperitoneal, rectal, intravenous, intramuscular, subcutaneous, intrauterine dural or cerebrovascular injection method. Most preferably, it is used for oral administration.

The dosage of the pharmaceutical composition of the present invention varies depending on the weight, age, sex, health condition, diet, time of administration, administration method, excretion rate and severity of the disease, but the daily dosage of the extract The amount is preferably 0.1 to 10 mg / kg, more preferably 3 to 9 mg / kg, more preferably 5 to 6 mg / kg, and may be administered 1 to 6 times a day. Can be.

The dosage unit may be, for example, one, two, three or four times the individual dosage, or one half, one third or one quarter. The individual dosage is preferably such that the effective drug is administered in one dose, which usually corresponds to all, 1/2, 1/3 or 1/4 times the daily dose.

The pharmaceutical composition of the present invention may further contain one or more active ingredients exhibiting the same or similar functions, and preferably contains Ecklonia cava, turmeric, ginger, wolfberry, omega 3 fatty acids known to exhibit dementia prevention and therapeutic effects. It may further comprise.

The pharmaceutical composition of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers.

In addition, the present invention provides a functional food composition for improving memory, improving cognition, preventing dementia, delaying or improving Gompi, turmeric, health and red ginseng extract as an active ingredient.

The functional food according to the present invention may be, for example, various functional foods such as chewing gum, caramel products, candy, ice cream, confectionery, beverage products such as soft drinks, mineral water, alcoholic beverages, and health functional foods including vitamins and minerals. Can be.

The extract of the present invention may be added as it is or used with other food or food ingredients, and may be appropriately used according to conventional methods. The blending amount of the active ingredient may be appropriately determined depending on the purpose of use (prevention, health or hygiene). In general, the extract of the present invention in the preparation of food or beverage may be added in an amount of up to 15% by weight, preferably up to 10% by weight relative to the raw material. However, in the case of long-term intake for health and hygiene or health control purposes, the amount may be below the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of safety.

The functional food of the present invention may contain various flavors, natural carbohydrates, and the like as additional ingredients. The above-mentioned natural carbohydrates may be glucose, monosaccharides such as fructose, disaccharides such as maltose, sucrose, and polysaccharides such as dextrin, cyclodextrin, sugar alcohols such as xylitol, sorbitol, erythritol and the like. As the sweetening agent, natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used.

The ratio of the natural carbohydrate is preferably selected in the range of 0.01 to 0.04 parts by weight, preferably about 0.02 to 0.03 parts by weight, per 100 parts by weight of the health food of the present invention.

In addition to the above, the functional food of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols. And carbonation agents used in carbonated beverages. In addition, the functional food of the present invention may contain a flesh for preparing natural fruit juice, fruit juice beverage and vegetable beverage. These components can be used independently or in combination. The ratio of such additives is not critical but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health food of the present invention.

Hereinafter, the present invention will be described in more detail with reference to Examples. Since these examples are only for illustrating the present invention, the scope of the present invention is not to be construed as being limited by these examples.

Example 1. Extract Preparation

Extracts were prepared using the ingredients of Gompi crushed, turmeric crushed, healthy slices and red ginseng crushed in a ratio of 1.5: 1.5: 1: 1 by weight. 50% (v / v) ethanol, which is 10 times (10 kg) based on the combined weight of raw materials (1 kg), is added, followed by extraction at 80 to 90 ° C. for 3 hours, and filtered with a 1 μm pore filter to obtain an extract. It was. Thereafter, 50% (v / v) ethanol in the same amount (10 kg) was added to the extraction residue obtained by filtration again, and extracted and filtered in the same manner to obtain an extract, which was then combined with the extract obtained first.

The extract obtained through two extractions was concentrated under reduced pressure under the conditions of about 60 ° C. and a vacuum degree of about 145 torr, and then dried at about 60 ° C. in a vacuum dryer for 12 hours. It was then crushed with a grinder and wrapped in aluminum foil for use in subsequent experiments.

The final extract (hereinafter referred to as 'WS-2') was 0.156g.

In addition, the extract was prepared in the same manner as above, but the extract was prepared using only red ginseng as a raw material and used as a positive control group.

Experimental Example 1. Analysis of the effect of improving memory and cognitive ability

To summarize the animal experiments to demonstrate the effect of improving memory and cognitive ability is shown in Table 1.

Experimental substance Laboratory animals Intake Biomarker Remarks
WS-2 ICR mice 5 weeks 500 mg / kg orally once a day Passive avoidance test Short-term working memory inspection Y-maze test Space Work Memory Inspection Morris water maze test Spatial Cognition Test

Experimental Animals: Male ICR mice, 3 weeks old, were purchased from Korea Experimental Animal Co., Ltd., and were acclimated according to the management criteria of the Laboratory Animal Laboratory, Woosuk University.

Sample administration: Mice were divided into groups (n = 10) so that the average body weight and dispersion were uniform, and placebo and WS-2 were dissolved orally in a solvent (water). Behavioral experiments were performed after 200 μl of WS-2 (500 mg / kg) was administered. The positive control group was administered red ginseng (100 mg / kg), and the negative control group was administered 200 μl of distilled water.

Preparation of beta amyloid infarction model by icv administration of beta amyloid (β) -42 After anesthetizing the mice, the epidermis of the bregma section was dissected by fixation to the stator. 5 μl of beta amyloid 42 (10 nmol) was taken with a specially prepared Hamilton syringe and injected into the auto injector (1 μl / sec) at a depth of 2.4 mm to be used as a model for behavioral experiments.

1-1. Short-term memory test: Passive-avoidance test

The passive avoidance memory test was performed using the Gemini evasion system. In the training experiment on the first day, the mouse was placed in a bright box, acclimated for 10 seconds, automatically opened the door to move to a dark box, and when moved to a dark box, 0.25 mA of electrical stimulation was applied for 3 seconds. It was. In the test experiment after 24 hours, the mouse was allowed to acclimate to the bright box for 10 seconds, and then the door was opened to move to the dark box. At this time, the time taken to move to the dark box was measured. On the second day, no electric stimulation was given. If the mouse does not move to the dark box for 120 seconds, a maximum score of 120 seconds is given.

Latency time in Acquisition trial: change in activity on day 1 of the experiment

Latency time in Retention trial on day 2 of the experiment

As a result of testing the short-term memory improvement effect of each candidate substance by passive avoidance method, red ginseng used as a positive control group showed the best effect on memory improvement as shown in FIG. 2, and WS-2 showed similar results when compared to red ginseng. It was.

1-2. Spatial work memory test: Y-maze test

A Y-maze composed of three branches (42 cm long, 3 cm wide, 12 cm high, 120 degrees) was used. Set each branch to A, B, C, carefully move the mouse to one branch, move it freely for 8 minutes, and record the branch where the mouse entered (only when the branch is fully inserted. record). One point (actual alteration) was given to three different branches in turn.

As a result of testing the spatial working memory improvement effect of each candidate substance, as shown in Figure 3, the effect of the red ginseng used as a positive control group showed the best effect on improving the spatial working memory memory, compared to the dementia model Aβ +, WS- 2 also showed good activity.

1-3. Spatial Cognitive Test: Morris water maze test

A circular bath was prepared and the water temperature was adjusted to about 25 ° C. Milk powder or vegetable dye was added to the water to make the water cloudy, and a small escape support (about 11 cm in diameter) was placed about 2 cm below the water surface. The mouse uses visual information to find clues in the lab where the support is located. The swimming path was recorded using a video tracking system, and the path length, swimming speed, time spent in each quadrant, and various variables were measured. The faster the animal finds its support, the shorter the swimming time (usually training to be 2 minutes). Removing the support will increase swimming time in the quadrant where the support was located. Finally, experiments with the flagged support can be used to evaluate sensory motor skills.

As a result of testing the spatial cognitive improvement effect of each candidate material, as shown in Figure 4 WS-2 showed a better activity than the red ginseng treatment group used as a positive control group.

Experimental Example 2. Histological examination: Immunohistochemistry

Immunohistochemistry is a method widely used in clinical practice because of the long-term preservation of stained specimens by specifically detecting specific substances in tissues using antigen-antibody reactions.

In order to prepare the samples before immunohistochemical staining, mice after the behavioral experiments were euthanized and brain tissues were extracted. After the tissue was fixed in a fixed solution containing formaldehyde for a certain period of time, frozen tissues or tissues fixed in the fixed solution were hardened in paraffin and cut into a thickness of 3 to 4 μm and attached to the slide. As the antigen process according to the characteristics of the antibody to be attached before attaching the primary antibody to the attached tissue, the commonly used target antigen retrieval solution and antigen retrieval method were used. Thereafter, peroxidase-blocking was performed to prevent endogenous peroxidase from being activated, and a primary antibody (antibody to Aβ) was attached (4 ° C. overnight). Then, a secondary antibody was added to the primary antibody, followed by a process for color development.

Through immunohistostaining, it is possible to visually see the accumulation of Aβ and the efficacy of drugs in tissues.

As a result of examining the efficacy of each candidate drug through immunostaining after animal experiments, WS-2 showed better activity than red ginseng used as a positive control in inhibiting the accumulation of Aβ in the cortex of the cerebral cortex as shown in FIGS. . Hippocampus, a hippocampal region, also showed good activity in WS-2. This indicates that WS-2 inhibits the accumulation of Aβ in the brain, as well as improving memory and cognitive abilities.

Experimental Example 3. Aβ aggregate observation

In order to analyze the effect on Aβ aggregation, Transmission electron microscopy (TEM) analysis was performed after inducing Aβ aggregation as follows.

After reacting Aβ 42 (20 μM) diluted with PBS for 20 minutes at room temperature, 5 μl of WS-2 (5.4 μM) and red ginseng (5.4 μM) as positive controls were added, respectively, and reacted at 37 ° C. for 0, 3 and 15 hours. I was. After the reaction was completed, 10µl of the sample was placed on 400mesh Copper grids (Formvar / Carbon, Electron Microscopy Science), dried, and washed twice with 5µl of Milli-Q water. Grids from which Milli-Q water was removed were stained with 10 μl of 1% uranyl acetate for 1 minute, and dried at room temperature for 15 minutes to obtain an image with a FEI G2 Spirit Twin microscope (Hitachi H-7650, Japan). At this time, three or more Aβ aggregates were secured for each sample, and three images were randomly selected, and the degree of Aβ aggregation was quantified by Image J2 (NIH). In order to measure the inhibitory activity against aggregation of Aβ 42, TEM analysis was performed to obtain three or more images, respectively (see FIGS. 9 and 10).

As a result of quantifying the Aβ aggregated from the image by Image J2, as shown in FIG. It showed a suppressed result compared to the negative control. On the other hand, compared with the anti-agglomeration effect of the red ginseng positive control group, it showed a coagulation inhibitory activity in a similar pattern to WS-2.

Claims (6)

An extract of 10-90% (v / v) ethanol extracted from a mixture of 1 to 2 parts by weight of turmeric, 0.5 to 1.5 parts by weight and 0.5 to 1.5 parts by weight of red ginseng as a solvent as an active ingredient A pharmaceutical composition for improving memory, improving cognitive ability, preventing dementia, delaying or treating. delete delete An extract of 10-90% (v / v) ethanol extracted from a mixture of 1 to 2 parts by weight of turmeric, 0.5 to 1.5 parts by weight and 0.5 to 1.5 parts by weight of red ginseng as a solvent as an active ingredient Functional food composition for improving memory, improving cognitive ability, preventing dementia, containing or improving.
delete delete

Images